Moreover, t(14;16) with a mutation in B-Raf proto-oncogene(BRAF) exits in a small subset of patients with newly diagnosed multiple myeloma, this mutation has been observed to be associated with an increased incidence of advanced refractory disease and unfavorable outcomes (35). Here, BRAF is linked to plasma cell myeloma.